Soluble CTLA-4 receptor an immunological marker of Graves' disease and severity of ophthalmopathy is associated with CTLA-4 Jo31 and CT60 gene polymorphisms

European Journal of Endocrinology

Volumn 161, Issue 5, 2009, Pages 787-793

  Daroszewski, Jacek ^a   Pawlak, Edyta ^b   Karabon, Lidia ^b   Frydecka, Irena ^a   Jonkisz, Anna ^a   Slowik, Miroslaw ^a   Bolanowski, Marek ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 RECEPTOR; DNA; LIOTHYRONINE; LYMPHOCYTE ANTIGEN RECEPTOR; THYROTROPIN; THYROXINE; UNCLASSIFIED DRUG; CYTOTOXIC T-LYMPHOCYTE ANTIGEN 4; LEUKOCYTE ANTIGEN;

ADULT; AGED; ALLELE; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE MARKER; DISEASE SEVERITY; EYE DISEASE; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GRAVES DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; ADOLESCENT; BLOOD; CHEMISTRY; COHORT ANALYSIS; ENDOCRINE OPHTHALMOPATHY; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; MIDDLE AGED; NONPARAMETRIC TEST; POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; COHORT STUDIES; DNA; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; GRAVES OPHTHALMOPATHY; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; STATISTICS, NONPARAMETRIC; THYROTROPIN; THYROXINE; TRIIODOTHYRONINE; YOUNG ADULT;

EID: 70449707279     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-09-0600     Document Type: Article

References (45)

1. Weetman AP. Autoimmune thyroid disease. Autoimmunity 2004 37 337-340.
2. Prabhakar BS, Bahn RS & Smith TJ. Current perspective on the pathogenesis of Graves' disease and ophthalmopathy. Endocrine Reviews 2003 24 802-835. (Pubitemid 38067700)
3. Weetman AP & McGregor AM. Autoimmune thyroid disease: further developments in our understanding. Endocrine Reviews 1994 15 788-830.
4. Heward J & Gough SC. Genetic susceptibility to the development of autoimmune disease. Clinical Science 1997 93 479-491. (Pubitemid 27517281)
5. Tomer Y & Davies TF. Searching for the autoimmune thyroid disease susceptibility genes: from gene mapping to gene function. Endocrine Reviews 2003 24 694-717. (Pubitemid 37330587)
6. Philippou G & McGregor AM. The aetiology of Graves' disease: what is the genetic contribution? Clinical Endocrinology 1998 48 393-395.
7. Chang TT, Kuchroo VK & Sharpe AH. Role of the B7-CD28/CTLA-4 pathway in autoimmune disease. Current Directions in Autoimmunity 2002 5 113-130.
8. Krummel MF & Allison JP. CD28 and CTLA-4 have opposing effects on response of T cells to stimulation. Journal of Experimental Medicine 1995 182 459-465.
9. Kosmaczewska A, Ciszak L, Bocko D & Frydecka I. Expression and functional significance of CTLA-4, a negative regulator of T cell activation. Archivum Immunologiae et Therapiae Experimentalis 2001 49 39-46. (Pubitemid 33611195)
10. Magistrelli G, Jeannin P, Herbault N, Benoit De CA, Gauchat JF, Bonnefoy JY & Delneste Y. A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells. European Journal of Immunology 1999 29 3596-3602. (Pubitemid 29527807)
11. Oaks MK & Hallett KM. Cutting edge: a soluble form of CTLA-4 in patients with autoimmune thyroid disease. Journal of Immunology 2000 164 5015-5018.
12. Oaks MK, Hallett KM, Penwell RT, Stauber EC, Warren SJ & Tector AJ. A native soluble form of CTLA-4. Cellular Immunology 2000 201 144-153.
13. Saverino D, Brizzolara R, Simone R, Chiappori A, Milintenda-Floriani F, Pesce G & Bagnasco M. Soluble CTLA-4 in autoimmune thyroid diseases: relationship with clinical status and possible role in the immune response dysregulation. Clinical Immunology 2007 123 190-198. (Pubitemid 46590071)
14. Pawlak E, Kochanowska IE, Frydecka I, Kielbinski M, Potoczek S & Bilinska M. The soluble CTLA-4 receptor: a new marker in autoimmune diseases. Archivum Immunologiae et Therapiae Experimentalis 2005 53 336-341. (Pubitemid 43186762)
15. Liu MF, Wang CR, Chen PC & Fung LL. Increased expression of soluble cytotoxic T-lymphocyte-associated antigen-4 molecule in patients with systemic lupus erythematosus. Scandinavian Journal of Immunology 2003 57 568-572. (Pubitemid 36734997)
16. Sato S, Fujimoto M, Hasegawa M, Komura K, Yanaba K, Hayakawa I, Matsushita T & Takehara K. Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis. Rheumatology 2004 43 1261-1266. (Pubitemid 39359301)
17. Pawlak E, Bilinska M, Suwalska K, Tutak A, Kosmaczewska A, Ciszak L & Frydecka I. Serum soluble CTLA-4 (sCTLA-4) levels in patients with multiple sclerosis. Polish Journal of Environmental Studies 2005 14 1261-1266.
18. Purohit S, Podolsky R, Collins C, Zheng W, Schatz D, Muir A, Hopkins D, Huang YH & She JX. Lack of correlation between the levels of soluble cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) and the CT-60 genotypes. Journal of Autoimmune Diseases 2005 2 8. (Pubitemid 41728565)
19. Mayans S, Lackovic K, Nyholm C, Lindgren P, Ruikka K, Eliasson M, Cilio CM & Holmberg D. CT60 genotype does not affect CTLA-4 isoform expression despite association to T1D and AITD in northern Sweden. BMC Medical Genetics 2007 8 3. (Pubitemid 46323228)
20. Momin S, Flores S, Angel BB, Codner DE, Carrasco PE & Perez-Bravo F. Interactions between programmed death 1 (PD-1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) gene polymorphisms in type 1 diabetes. Diabetes Research and Clinical Practice 2009 83 289-294.
21. Wang XB, Kakoulidou M, Giscombe R, Qiu Q, Huang D, Pirskanen R & Lefvert AK. Abnormal expression of CTLA-4 by T cells from patients with myasthenia gravis: effect of an AT-rich gene sequence. Journal of Neuroimmunology 2002 130 224-232. (Pubitemid 35240010)
22. Gu M, Kakoulidou M, Giscombe R, Pirskanen R, Lefvert AK, Klareskog L & Lefvert AK. Identification of CTLA-4 isoforms produced by alternative splicing and their association with myasthenia gravis. Clinical Immunology 2008 128 374-381.
23. Li X, Xiao BG, Lu CZ & Lu JH. Decrease of CD4+CD25high-Foxp3+ regulatory T cells and elevation of Cd19+BAFF-R+B cells and soluble ICAM-1 in myasthenia gravis. Clinical Immunology 2008 126 180-188.
24. Luszczek W, Kubicka W, Jasek M, Baran E, Cislo M, Nockowski P, Luczywo-Rudy M, Wisniewski A, Nowak I & Kusnierczyk P. CTLA-4 gene polymorphisms and natural soluble CTLA-4 protein in psoriasis vulgaris. International Journal of Immunogenetics 2006 33 217-224. (Pubitemid 43781726)
25. Berry A, Tector M & Oaks MK. Lack of association between sCTLA-4 levels in human plasma and common CTLA-4 polymorphisms. Journal of Negative Results in Biomedicine 2008 7 8.
26. Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell'Unto E, Bruno-Bossio G, Nardi M, Bartolomei MP, Lepri A, Rossi G, Martino E & Pinchera A. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. New England Journal of Medicine 1998 338 73-78. (Pubitemid 28042269)
27. Marcocci C, Bartalena L, Tanda ML, Manetti L, Dell'Unto E, Rocchi R, Barbesino G, Mazzi B, Bartolomei MP, Lepri P, Cartei F, Nardi M & Pinchera A. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study. Journal of Clinical Endocrinology and Metabolism 2001 86 3562-3567. (Pubitemid 32755944)
28. Pinchera A,WiersingaW, Glinoer D, Kendall-Taylor P, Koornneef L, Marcocci C, Schleusensr H, Romaldi J, Niepominiszcze H, Negataki S, Izumi M, Inoune Y, Stockigt J, Wall J, Greenspan F, Solomon D, Garrity J & Gorman CA. Classification of eye changes of Grave's disease. Thyroid 1992 2 235-236.
29. Mourits MP, Koornneef L, Wiersinga WM, Prummel MF, Berghout A & van der Gaag R. Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach. British Journal of Ophthalmology 1989 73 639-644. (Pubitemid 19202075)
30. Suwalska K, Pawlak E, Karabon L, Tomkiewicz A, Dobosz T, Urbaniak-Kujda D, Kuliczkowski K, Wolowiec D, Jedynak A & Frydecka I. Association studies of CTLA-4, CD28, and ICOS gene polymorphisms with B-cell chronic lymphocytic leukemia in the Polish population. Human Immunology 2008 69 193-201.
31. Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G, Rainbow DB, Hunter KM, Smith AN, Di GG, Herr MH, Dahlman I, Payne F, Smyth D, Lowe C, Twells RC, Howlett S, Healy B, Nutland S, Rance HE, Everett V, Smink LJ, Lam AC, Cordell HJ, Walker NM, Bordin C, Hulme J, Motzo C, Cucca F, Hess JF, Metzker ML, Rogers J, Gregory S, Allahabadia A, Nithiyananthan R, Tuomilehto-Wolf E, Tuomilehto J, Bingley P, Gillespie KM, Undlien DE, Ronningen KS, Guja C, Ionescu-Tirgoviste C, Savage DA, Maxwell AP, Carson DJ, Patterson CC, Franklyn JA, Clayton DG, Peterson LB, Wicker LS, Todd JA & Gough SC. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003 423 506-510. (Pubitemid 36648570)
32. Bartalena L, Martino E, Marcocci C, Bogazzi F, Panicucci M, Velluzzi F, Loviselli A & Pinchera A. More on smoking habits and Graves' ophthalmopathy. Journal of Endocrinological Investigation 1989 12 733-737. (Pubitemid 20013854)
33. Perros P, Crombie AL, Matthews JN & Kendall-Taylor P. Age and gender influence the severity of thyroid-associated ophthalmopathy: a study of 101 patients attending a combined thyroid-eye clinic. Clinical Endocrinology 1993 38 367-372. (Pubitemid 23105068)
34. Kavvoura FK, Akamizu T, Awata T, Ban Y, Chistiakov DA, Frydecka I, Ghaderi A, Gough SC, Hiromatsu Y, Ploski R, Wang PW, Ban Y, Bednarczuk T, Chistiakova EI, Chojm M, Heward JM, Hiratani H, Juo SH, Karabon L, Katayama S, Kurihara S, Liu RT, Miyake I, Omrani GH, Pawlak E, Taniyama M, Tozaki T & Ioannidis JP. CTLA-4 gene polymorphisms and autoimmune thyroid disease: a meta analysis. Journal of Clinical Endocrinology and Metabolism 2007 92 3162-3170.
35. Ban Y, Concepcion ES, Villanueva RB, Greenberg DA, Davies TF & Tomer Y. Analysis of immune regulatory genes in familial and sporadic Graves' disease. Journal of Clinical Endocrinology and Metabolism 2004 89 4562-4568. (Pubitemid 39244470)
36. Kouki T, Sawai Y, Gardine CA, Fisfalen ME, Alegre ML & DeGroot LJ. CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves' disease. Journal of Immunology 2000 165 6606-6611.
37. Takara M, Kouki T & DeGroot LJ. CTLA-4 AT-repeat polymorphism reduces the inhibitory function of CTLA-4 in Graves' disease. Thyroid 2003 13 1083-1089. (Pubitemid 38032393)
38. Yanagawa T, Hidaka Y, Guimaraes V, Soliman M & DeGroot LJ. CTLA-4 gene polymorphism associated with Graves' disease in a Caucasian population. Journal of Clinical Endocrinology and Metabolism 1995 80 41-45.
39. Kouki T, Gardine CA, Yanagawa T & Degroot LJ. Relation of three polymorphisms of the CTLA-4 gene in patients with Graves' disease. Journal of Endocrinological Investigation 2002 25 208-213. (Pubitemid 34295874)
40. Petrone A, Giorgi G, Galgani A, Alemanno I, Corsello SM, Signore A, Di Mario U, Nistico L, Cascino I & Buzzetti R. CT60 single nucleotide polymorphisms of the cytotoxic T-lymphocyte-associated antigen-4 gene region is associated with Graves' disease in an Italian population. Thyroid 2005 15 232-238. (Pubitemid 40418690)
41. Ban Y, Tozaki T, Taniyama M, Tomita M & Ban Y. Association of a CTLA-4 30 untranslated region (CT60) single nucleotide polymorphism with autoimmune thyroid disease in the Japanese population. Autoimmunity 2005 38 151-153. (Pubitemid 40872739)
42. Weng YC,Wu MJ & Lin WS. CT60 single nucleotide polymorphism of the CTLA-4 gene is associated with susceptibility to Graves' disease in the Taiwanese population. Annals of Clinical and Laboratory Science 2005 35 259-262.
43. Bednarczuk T, Gopinath B, Ploski R & Wall JR. Susceptibility genes in Graves' ophthalmopathy: searching for a needle in a haystack? Clinical Endocrinology 2007 67 3-19.
44. Frydecka I, Daroszewski J, Suwalska K, Zoledziowska M, Tutak A, Slowik M, Potoczek S & Dobosz T. CTLA-4 (CD152) gene polymorphism at position 49 in exon 1 in Graves' disease in a Polish population of the Lower Silesian region. Archivum Immunologiae et Therapiae Experimentalis 2004 52 369-374. (Pubitemid 39627943)
45. Han S, Zhang S, Zhang W, Li R, Li Y, Wang Z, Xie Y & Mao Y. CTLA4 polymorphisms and ophthalmopathy in Graves' disease patients: association study and meat-analysis. Human Immunology 2006 67 618-626. (Pubitemid 44205330)